{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Menard M"],"funding":["Alex's Lemonade Stand Foundation","Cancer Research UK","National Cancer Center","Uehara Memorial Foundation","National Institutes of Health","Alex’s Lemonade Stand Foundation","U.S. Department of Defense","St. Baldrick's Foundation","NCI NIH HHS","NINDS NIH HHS","Efim Guzik chair","St. Baldrick’s Foundation","NIH HHS"],"pagination":["e20231417"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12263170"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["222(9)"],"pubmed_abstract":["Neuroblastomas are highly heterogeneous tumors originating from neural crest-derived cells destined to form the sympathetic nervous system. Nearly half of high-risk tumors present with amplification of the MYCN proto-oncogene. Here, we describe a Mycn-driven, transplantable, non-germline, genetically engineered mouse model (Mycn-nGEMM). Mycn-nGEMM tumors recapitulate the immune-evasive, macrophage-rich tumor microenvironment of high-risk, MYCN-amplified human neuroblastoma. Treatment of tumor-bearing mice with anti-PD-L1, but not anti-PD-1 or anti-CTLA-4, inhibited tumor growth, profoundly remodeling the tumor microenvironment by depleting anti-inflammatory macrophages and increasing T cell infiltration. Surprisingly, while tumor cells showed low expression of PD-L1, anti-inflammatory macr"],"journal":["The Journal of experimental medicine"],"pubmed_title":["Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma."],"pmcid":["PMC12263170"],"funding_grant_id":["U01CA217864","CA170257P1","P30 CA082103","P01 CA217959","P30CA82103","R01 NS125668","U01 CA217864","R01NS125668","P01CA217959"],"pubmed_authors":["Maris JM","Asgharzadeh S","Lopez V","Grossmann LD","Nasholm N","McHenry L","Gustafson WC","Farrel A","Wang L","Barata MJ","Yoda H","Lu ED","Shimada H","Kaufman R","Fernandez GE","Wong-Michalak S","Menard M","Simonds EF","Kennedy RJ","Weiss WA"],"additional_accession":[]},"is_claimable":false,"name":"Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma.","description":"Neuroblastomas are highly heterogeneous tumors originating from neural crest-derived cells destined to form the sympathetic nervous system. Nearly half of high-risk tumors present with amplification of the MYCN proto-oncogene. Here, we describe a Mycn-driven, transplantable, non-germline, genetically engineered mouse model (Mycn-nGEMM). Mycn-nGEMM tumors recapitulate the immune-evasive, macrophage-rich tumor microenvironment of high-risk, MYCN-amplified human neuroblastoma. Treatment of tumor-bearing mice with anti-PD-L1, but not anti-PD-1 or anti-CTLA-4, inhibited tumor growth, profoundly remodeling the tumor microenvironment by depleting anti-inflammatory macrophages and increasing T cell infiltration. Surprisingly, while tumor cells showed low expression of PD-L1, anti-inflammatory macr","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-07-16T23:39:52.891Z","creation":"2026-07-12T03:11:45.947Z"},"accession":"S-EPMC12263170","cross_references":{"pubmed":["40658105"],"doi":["10.1084/jem.20231417"]}}